Ads
related to: carboplatin chemotherapy- Overall Survival Results
See Updated Overall Survival Data
For This Treatment Option
- Dosing & Administration
Read More About Dosing
And How To Prescribe
- Official Video Library
See A Medical Expert Discuss
Overall Survival Data For mBC
- Patient Support
View The The Service Request Form
To Gain Access To Support Programs
- Financial Resources
Learn About The Available Access
Programs For Your Patients
- Safety Profile
View The Full Safety Profile And
See Side Effects For This Option
- Overall Survival Results
Search results
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 8 hours agoEGFR is overexpressed in tumour cells and involved in cell proliferation. Johnson & Johnson’s...
ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena via Yahoo Finance· 10 hours agoThe therapy was evaluated as a monotherapy and in combination with AbbVie’s investigative programmed...
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 2 days agoCompared to the chemotherapy control, ivonescimab plus...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Valley City Times Record· 3 days agoJohnson & Johnson today announced new data from the Phase 3 MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVANT® (amivantamab-vmjw) in combination with lazertinib ...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 4 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
Merck’s KEYTRUDA shows survival benefits in Phase III TNBC trial
Clinical Trials Arena via Yahoo Finance· 5 days agoParticipants were assigned in a 2:1 ratio to receive either KEYTRUDA with chemotherapy or a...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Quincy Herald-Whig· 3 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting...
Digital Journal· 1 day agoEarly efficacy data from the phase Ib/II trial TRIFOUR, NCT05181462 , also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin ...
Carefully Designing De-escalation Trials in Breast Cancer
Medscape· 5 days agoDe-escalation trials in early breast cancer are "critical to preserving quality of life" but require...
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
MedPage Today· 3 days agoChina-based trial may present a hurdle to FDA approval, however
Ads
related to: carboplatin chemotherapy